Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Flamel Technologies — Investor Presentation (March 2016)

37 slides from Avadel Pharmaceuticals's investor presentation, Mar 14, 2016

  1. Slide 1: March 2016 1

    March 2016 1

  2. Slide 2: Forward Looking Statements

    March 2016 2 Forward Looking Statements This document includes statements concerning our operating results (including product sales), financial condition and product development milestones, which are “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of

  3. Slide 3: Flamel Technologies Transformed

    March 2016 3 Flamel Technologies Transformed • Strong financial condition - profitable with strong cash flow and balance sheet • Expanding commercialization product portfolio: ▪ Two FDA approved products from the Eclat portfolio and a third expected in 2016 ▪ Four pediatric products via FSC Pediatri

  4. Slide 4: Key Milestones Achieved in 2015

    March 2016 4 Key Milestones Achieved in 2015 x Generated $173.2 million of revenues x Profitable and cash flow positive for first time in Company's history x Had successful meeting with FDA on Micropump ® Sodium Oxybate x Presented positive clinical data • LiquiTime ® guaifenesin • Trigger Lock™ hyd

  5. Slide 5: 2016 Expectations

    March 2016 5 2016 Expectations • Integrate and market newly acquired FSC Pediatrics’ products • Complete and report data from Phase 1b study with Medusa™ exenatide in patients • Commence patient registration and dosing for pivotal study of Micropump ® sodium oxybate • Launch UMD#3 following April 30

  6. Slide 6: Acquisition of FSC

    March 2016 6 Acquisition of FSC

  7. Slide 7: Strategic Rationale and Transaction Terms: FSC Pediatrics

    March 2016 7 Strategic Rationale FSC Pediatrics • Commercial stage specialty pharmaceuticals company headquartered Charlotte, NC • Provides commercial infrastructure to leverage for future products • Provides new revenue stream from four FSC products and lessens dependence on Éclat products • Positi

  8. Slide 8: FSC Sales Force Coverage

    March 2016 8 FSC Sales Force Coverage

  9. Slide 9: Marketed Products Portfolio

    March 2016 9 Marketed Products Portfolio • Flamel’s Products • FSC Products

  10. Slide 10: Bloxiverz & Vazculep Overview

    March 2016 10 BLOXIVERZ® & VAZCULEP ® Overview * IMS Bloxiverz ® • Indication: Reverses neuromuscular blockades used in surgical procedures • 1 of 3 approved versions of neostigmine methylsulfate injection • Approximately 4 million vials sold annually in the United States* • More details can be foun

  11. Slide 11: Karbinal ER & Cefaclor Overview

    March 2016 11 KARBINAL™ ER & CEFACLOR Overview • Licensed from Tris Pharma in August 2013 • Used for the treatment of seasonal and perennial allergic rhinitis in children 2 years of age and older • Orange book patent protection through March 2029 • Market size for liquids in US estimated at $110 mil

  12. Slide 12: Aciphex Sprinkle Overview

    March 2016 12 ACIPHEX® SPRINKLE™ Overview • Licensed from Eisai in June 2014 • FDA approved AcipHex Sprinkle in March 2013 for the treatment of GERD in pediatric patients aged 1 - 11 years • Launched promotional efforts in August 2014 • Market size for liquids in US estimated at $110 million • Proto

  13. Slide 13: FlexiChamber Overview

    March 2016 13 FLEXICHAMBER® Overview • Collapsible asthma spacer • Internally developed with a 510 (K) clearance • Market size estimated at $50 million • Patents through 2028 • Patient benefits: x Dynamic Portability x Optimal Performance x Simple Assembly x Enhanced Patient Care TRANSFORMING THE TR

  14. Slide 14: Flamel's R&D Pipeline

    March 2016 14 Flamel’s R&D Pipeline • Micropump® sodium oxybate • LiquiTime® • Trigger Lock™ hydromorphone • Medusa™ e xenatide

  15. Slide 15: Current Pipeline

    March 2016 15 Drug/ Technology Indication Proof of Concept Pilot Pivotal Under Review Approved Sales Force UD/UMD 1 # 3 Undisclosed Flamel UD/UMD 1 # 4 Undisclosed Flamel Sodium oxybate/ Micropump® Narcolepsy Flamel Ibuprofen / LiquiTime ® Pain / Fever Perrigo Guaifenesin / LiquiTime ® Respiratory P

  16. Slide 16: Micropump Sodium Oxybate (FT218)

    March 2016 16 FT218 Overview • Extended release oral solid formulation of sodium oxybate using Micropump ® • Studied in 40 healthy volunteers across 2 studies • Profile is consistent with the target of single dose before bedtime • Met with FDA mid 2015 and will submit IND and SPA during 1H 2016 • Ne

  17. Slide 17: LiquiTime OTC

    March 2016 17 Overview • Extended release liquid oral suspension for treatment of pain and fever • Ibuprofen & Guaifenesin oral suspension twice - daily dosing confirmed Next Step : • Ibuprofen – IND/CTA filing and pivotal trial initiation in 2 H 2016 • Guaifenesin – Confirmatory PK study in 1 H 201

  18. Slide 18: Trigger Lock Hydromorphone (FT227)

    March 2016 18 FT227 Overview • Abuse - deterrent, extended - release, oral hydromorphone product for treatment of pain – technology is applicable to all opioids • Positive results from two pilot PK studies in healthy volunteers announced in June 2015 • Next step : M eet with the FDA in 1 H 2016 ; be

  19. Slide 19: Medusa Exenatide (FT228)

    March 2016 19 FT228 Overview • Subcutaneous injection formulation of exenatide , a GLP - 1 (glucagon - like peptide – 1 ) for treatment of Type 2 diabetes • Interim phase I human clinical data reported in December 2015 • PK profile compatible with a release over one week in humans • Next step : Comp

  20. Slide 20: Flamel's Strengths

    March 2016 20 Flamel’s Strengths • Strong intellectual property • Seasoned senior management • Healthy financial situation

  21. Slide 21: Strong Intellectual Property

    March 2016 21 Strong Intellectual Property *New patents may be issued targeting each individual product in development where a Flamel drug delivery platform is applied to a specific molecule Platform US Europe Micropump® July 2027 July 2023 LiquiTime® September 2025 April 2023 Trigger Lock™ April 20

  22. Slide 22: Seasoned Senior Management

    March 2016 22 Seasoned Senior Management Name Title Appointed Experience Michael S. Anderson Chief Executive Officer 2012 40+ years Pharma Sandy Hatten Senior Vice President, Quality and Regulatory Affairs 2015 30+ years Pharma Phillandas T. Thompson, J.D., M.B.A. Senior Vice President, General Coun

  23. Slide 23: Condensed Consolidated Statement of Operations

    March 2016 23 Condensed Consolidated Statement of Operations (Unaudited) In USD million, except EPS and shares data (million) Twelve months ended December 31, 2015 December 31, 2014 Revenue $ 173.2 $14.8 COGS (10.9) (3.4) R&D (25.6) (17.3) SG&A (21.7) (15.7) Acquisition Royalty Payments (32.2) (1.7)

  24. Slide 24: Key Financial Metrics

    March 2016 24 Key Financial Metrics (Unaudited) Income Statement Metrics Twelve months ended December 31, 2015 2014 Revenue $ 173.2 $14.8 COGS (10.9) (3.4) R&D (25.6) (17.3) SG&A (21.7) (15.7) Acquisition Earn - Out Payments/Accruals (32.2) (1.7) Adj Op. Profit (Loss) * 82.8 (23.3) Adj. Net Income (

  25. Slide 25: Flamel Technologies Transformed

    March 2016 25 Flamel Technologies Transformed • Strong financial condition - profitable with strong cash flow and balance sheet • Expanding commercialization product portfolio: ▪ Two FDA approved products from the Eclat portfolio and a third expected in 2016 ▪ Four pediatric products via FSC Pediatr

  26. Slide 26: Appendix

    March 2016 26 Appendix

  27. Slide 27: Diversified and Proven Drug Delivery Platforms

    March 2016 27 Diversified and Proven Drug Delivery Platforms • Outstanding drug delivery platforms to tackle key challenges in the formulation, in various dosage forms (e . g . capsules, tablets, sachets or oral liquid suspensions ; or injectable for subcutaneous administration) of a broad range of

  28. Slide 28: Micropump Platform at a Glance

    March 2016 28 Micropump® Platform a t a Glance • Extended/delayed - release of drugs in the GI tract • Precise pharmacokinetics of single or combination of drugs in various formats • Numerous Micropump® - based products successfully tested in human clinical trials Various dosage forms (tablet, capsu

  29. Slide 29: Micropump Microparticles for Controlled/Modified Release

    March 2016 29 • Microparticles are dispersed in the stomach and pass into the small intestine, after which each microparticle releases the drug at an adjustable rate and over an extended period of time (up to 24 hours) • Drug released at an adjustable rate controlled and/or delayed • Micropump® micr

  30. Slide 30: LiquiTime Platform at a Glance

    March 2016 30 LiquiTime® Platform at a Glance LiquiTime® is a novel, proprietary and innovative delivery platform allowing the stable L iquid and controlled release formulation of one or several combined drugs over Time LiquiTime® meets challenges faced in the treatment of pediatric and geriatric pa

  31. Slide 31: LiquiTime for Extended-Release Liquid Suspension

    March 2016 31 Each microparticle is individually coated and behaves as an independent micro reservoir Coating • controls diffusion • keeps its integrity • offers good resistance to stress LiquiTime® f or Extended - Release Liquid Suspension L iquid suspension contains small coated drug microparticle

  32. Slide 32: Trigger Lock Platform at a Glance

    March 2016 32 Trigger Lock™ is a proprietary and innovative delivery platform that enables the controlled release of narcotic and opioid analgesics while deterring their abuse Trigger Lock™ successfully addresses the issues of narcotic/opioid analgesics tampering : x The sustained release Micropump®

  33. Slide 33: Trigger Lock SR Microparticles for Abuse Resistance

    March 2016 33 1. Drug loaded Micropump® microparticles Sustained Release (SR) microparticles which are resistant to crushing 2. Viscosifying ingredient(s) To prevent abuse by injection after extraction in a small volume of solvent 3. Quenching ingredient(s) To prevent extraction in large volumes of

  34. Slide 34: Medusa Platform at a Glance

    March 2016 34 Medusa Depot Solubilization and stabilization of drugs Applicable to a wide range of small molecules, peptide and protein drugs Safe, non - immunogenic and fully biodegradable Sustained delivery from 1 to 7 days in human Combination of several different drugs in the same formulation Bi

  35. Slide 35: Medusa Depot for Injection

    March 2016 35 Medusa ™ Depot for Injection COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + Vitamin E Polyglutamate chain Drug solution or powder Formulation by simple mixing in water Non - covalent association ( reversible hydrophobic and/or electrostatic interaction) of

  36. Slide 36: Reconciliation of Non GAAP to GAAP Results

    March 2016 36 Reconciliation of Non GAAP to GAAP Results

  37. Slide 37: Headquarters and Contact

    March 2016 37 Headquarters 33 avenue du Dr . Georges Levy 69200 Vénissieux (Lyon) France U . S . Commercial Operations 16640 Chesterfield Grove Road, Suite 200 Chesterfield, MO Corporate Contact Phone : + 33 472 783 434 Fax : + 33 472 783 435 E - mail : licensing@flamel . com Specialty Pharmaceutica

Flamel Technologies — Investor Presentation (March 2016) on 6ix